Transpulmonary Thermodilution Measurements in Patients With Heart Diseases

Phase 4CompletedNCT02035007

University of Zurich70 enrolled

Overview

The purpose of this study is to examine the validation of the PiCCO (Pulse Contour Cardiac Output)-derived transpulmonary thermodilution technology in patients with heart diseases.

* How do PiCCO and PAC (pulmonary artery catheter) derived hemodynamic variables change in different cardiac pathologies? * How do PiCCO hemodynamic variables compare to transthoracic echocardiographic parameters in different cardiac pathologies? * How does GEDV (global enddiastolic volume) correlate with left ventricles end-diastolic volume (LVEDV) assessed by LV (left ventricle) ventriculography and echocardiography? * How do PiCCO cardiac function variables (GEF \[global ejection fraction\]; CFI \[cardiac function index\]) correlate with LV dP/dt max, LVEF (left ventricular ejection fraction) assessed by LV ventriculography and echocardiography, LVFAC (left ventricular fractional area of change), LV stroke work index (LVSWI) and cardiac power (CP)? * How does GEDV compare to LVEDV and left ventricular end-diastolic pressure (LVEDP) as assessed by the pulmonary artery occlusion pressure (PAOP)? * How does right ventricular function influence GEDV, GEF and CFI?

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Heart Diseases

Interventions

PiCCO Catheter (Pulsiocath 5F)DEVICE

Measuring of PiCCO derived values

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * Coronary heart disease without impaired left ventricular function \[LV-EF \> 50%\] (n=10, control group) * Coronary heart disease with impaired left ventricular function \[LV-EF \< 50%\] (n=10) * Dilated cardiomyopathy (n=10), * Aortic valve stenosis (n=10), * Mitral valve regurgitation (n=10), * Diastolic left ventricular dysfunction (n=10) and * Right heart failure (n=10) Exclusion criteria: * Patients with catecholamine dependent cardiogenic shock, severe respiratory distress because of pulmonary oedema, intubated patients, patients with atrial fibrillation, atrioventricular conduction abnormalities, and slow ventricular tachycardia will not be included. * Moreover patients not being able to give informed consent are excluded. Even more, pregnant women are excluded from the study due to the radiation exposure in line with heart catheterization. A pregnancy test will be performed prior to participating with this study. * The age does not represent an exclusion criterion.

Locations (1)

Medical Intensive Care Unit, University Hospital of Zurich

Zurich, Canton of Zurich, Switzerland

Outcomes

Primary Outcomes

Cardiac Output, Preload values (GEDV)

Outcome measure is obtained during PiCCO measurement and left/right heart catherization, respectively ("point-of-care" measurement). There is no follow-up examination thereafter.

Time frame: Day 1 only

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.